6 Minutes
by Michael Woodhead
August 20, 2010
Immunisation experts say there is no immediate need to consider switching from the current quadrivalent HPV vaccine (Gardasil) to a ‘stronger’ bivalent vaccine (Cervarix).
The First International HPV Vaccine Information Clearinghouse
6 Minutes
by Michael Woodhead
August 20, 2010
Immunisation experts say there is no immediate need to consider switching from the current quadrivalent HPV vaccine (Gardasil) to a ‘stronger’ bivalent vaccine (Cervarix).
HPV 2010 Conference
Montreal Canada
July 3-8, 2010
Conclusion: Our data do not provide sufficient evidence to modify existing 3-dose schedules, but suggest that fewer than three doses may provide a high degree of protection against HPV-16/18 infection. Systematic evaluation of one- and two-dose schedules is justified.
The Hindu News
August 9, 2010
Aarti Dhar
Information on the demonstration project and licensing of two vaccines to prevent cervical cancer has been exempted from public disclosure under Section 8 of the Right to Information Act, 2005.